Physician profile
Wendy C Magee
NPI 1760484349
$27,238.80
in general payments reported to CMS, 2019-2025
46 companies · $4,615 in 2025
The $4,615 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,149 · 2020: $1,963 · 2021: $2,538 · 2022: $3,008 · 2023: $4,805 · 2024: $4,162 · 2025: $4,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,317.19 |
| Education | $264.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $6,460.32 | 2019-2025 | |
| Abbvie INC. | $3,398.56 | 2019-2025 | |
| Janssen Biotech, INC. | $1,983.51 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $1,424.39 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,368.22 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,292.76 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Leo Pharma INC. | $1,284.11 | 2019-2025 | Adbry |
| Lilly USA, LLC | $1,126.85 | 2019-2025 | Taltz, Ebglyss |
| Amgen INC. | $1,061.65 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $856.56 | 2023-2025 | Zoryve |
| Ucb, INC. | $853.53 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $808.45 | 2019-2025 | |
| Incyte Corporation | $733.16 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $599.29 | 2020-2025 | Sotyktu |
| Dermavant Sciences, INC. | $447.45 | 2022-2024 | Vtama |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $433.20 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $343.91 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Paratek Pharmaceuticals, INC. | $320.69 | 2021-2025 | Nuzyra |
| Hill Dermaceuticals, INC. | $280.00 | 2020-2025 | Tolak |
| Mayne Pharma Commercial LLC | $256.17 | 2019-2025 | |
| Almirall LLC | $222.40 | 2019-2025 | Klisyri, Seysara |
| Organogenesis INC. | $217.24 | 2021-2024 | Puraply |
| Celgene Corporation | $213.38 | 2019 | |
| Organon LLC | $202.01 | 2025 | Vtama |
| Epi Health, LLC | $169.66 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $108.14 | 2024-2025 | Acthar |
| Dermira, INC. | $99.17 | 2019-2021 | |
| Journey Medical Corporation | $94.28 | 2019-2021 | |
| Genentech USA, INC. | $81.09 | 2020-2022 | |
| Medimetriks Pharmaceuticals, INC. | $63.95 | 2020-2021 | |
| Vyne Pharmaceuticals INC. | $52.07 | 2020 | |
| Encore Dermatology INC. | $48.71 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $39.28 | 2025 | Ycanth |
| Tempus Ai, INC | $37.21 | 2024 | Merlin Test |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.04 | 2022-2024 | Spevigo |
| Dusa Pharmaceuticals, INC. | $30.10 | 2019 | |
| Springworks Therapeutics, INC. | $28.04 | 2025 | Gomekli |
| Nabriva Therapeutics, Plc | $27.22 | 2020-2022 | |
| Biofrontera INC. | $25.62 | 2021 | |
| Kerecis Limited | $24.18 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Teva Pharmaceuticals USA, INC. | $19.85 | 2024 | Simlandi |
| Helsinn Therapeutics (U.S.), INC. | $15.78 | 2024 | Valchlor |
| Astrazeneca Pharmaceuticals LP | $15.45 | 2023 | Evusheld |
| Melinta Therapeutics, LLC | $11.57 | 2019 | |
| Promius Pharma LLC | $11.42 | 2019 | |
| Aclaris Therapeutics, INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Magee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.